OverviewSuggest Edit

LianBio is a biopharmaceutical company that designs and provides innovative drugs and treatments for oncology and cardiology diseases. The company aims to accelerate the development and expand the availability of medicines to help patients with transformative mechanisms and precision-based therapeutics.

HQShanghai, CN

Latest Updates

Employees (est.) (Sept 2021)38(+23%)
Cybersecurity ratingAMore

Key People/Management at LianBio

Debra Yu

Debra Yu

President & CBO
Jing Ji

Jing Ji

SVP, Medical and Clinical Development
Nathan Chen

Nathan Chen

VP, Regulatory Affairs
Jennifer Huang

Jennifer Huang

VP, Legal & Compliance
Tao Ji

Tao Ji

VP, China Finance
Konstantin Poukalov

Konstantin Poukalov

Executive Chairman
Show more

LianBio Office Locations

LianBio has offices in Shanghai and Princeton
Shanghai, CN (HQ)
1155 Fangdian Rd, Shi Ji Gong Yuan, Pudong Xinqu
Princeton, NJ, US
103 Carnegie Center Dr #215
Show all (2)

LianBio Financials and Metrics

Summary Metrics

Founding Date


LianBio total Funding

$310 m

LianBio latest funding size

$310 m

Time since last funding

a year ago

LianBio investors

LianBio's latest funding round in October 2020 was reported to be $310 m. In total, LianBio has raised $310 m
Show all financial metrics

LianBio Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

LianBio Online and Social Media Presence

Embed Graph

LianBio News and Updates

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

BLACKSBURG, Va., and SHANGHAI, China and PRINCETON, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, and LianBio, a biotechnology c…

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease

Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China, the world’s second largest healthcare market Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 m…

LianBio Frequently Asked Questions

  • When was LianBio founded?

    LianBio was founded in 2019.

  • Who are LianBio key executives?

    LianBio's key executives are Debra Yu, Jing Ji and Nathan Chen.

  • How many employees does LianBio have?

    LianBio has 38 employees.

  • Who are LianBio competitors?

    Competitors of LianBio include SHINKEI Therapeutics, Yamo Pharmaceuticals and Biodol Therapeutics.

  • Where is LianBio headquarters?

    LianBio headquarters is located at 1155 Fangdian Rd, Shi Ji Gong Yuan, Pudong Xinqu, Shanghai.

  • Where are LianBio offices?

    LianBio has offices in Shanghai and Princeton.

  • How many offices does LianBio have?

    LianBio has 2 offices.